NEW YORK (GenomeWeb News) — Sigma-Aldrich today said it has licensed from Epigentek technology for DNA modification, methylation quantitation, and protein/DNA interaction, which Sigma plans to use to develop its planned epigenetics research products.
The license is exclusive in the US and co-exclusive globally, Sigma-Aldrich said.
Keith Jolliff, Sigma-Aldrich’s director of Genomics and Functional Genomics, said the agreement “is an excellent entry point to supporting epigenetics research,” which he said the company has identified “as a growing area of interest and research for heritable diseases such as cancer, Alzheimer’s, and many others.”
Sigma-Aldrich plans to launch a family of products for epigenetic research, beginning with the Imprint DNA Modification Kit, which it will launch this month. Other products planned under the Imprint brand include kits for global methylation quantitation and chromatin immunoprecipitation based on Epigentek's technologies.
Financial terms of the agreement were not disclosed.